05) and returned to normal values with renal recovery post-LT. In the validation set (n = 46), a number of proteins were significantly higher in both rAKI and iAKI versus nAKI. However, only pre-LT plasma OPN (P = 0.009) and TIMP-1 (P = 0.019) levels were significantly higher in rAKI versus iAKI. Logistic regression modeling was used to correlate the probability of post-LT rAKI, factoring in both pre-LT protein markers and clinical variables. A combined model including

elevated OPN and TIMP-1 levels, age <57, and absence of diabetes had the highest area under the curve of 0.82, compared to protein-only and clinical variable–only models. Conclusion: These data suggest that plasma protein profiles might improve the prediction of pre-LT kidney injury recovery after LT. However, multicenter, prospective studies FK506 cell line are needed to validate these findings and Atezolizumab ic50 ultimately test the value of such protein panels in perioperative management

and decision making. (Hepatology 2014;60:2016–2025) “
“A significance number of autoantibodies have been reported in patients with Non Alcoholic Fatty Liver Disease (NAFLD) patients. In the present study, our aim was to assess the role of disease and cell-specific antibodies, namely anti-adipocyte antibodies (anti-AdAb) in patients with NAFLD and Non Alcoholic Steatohepatitis (NASH). Flow Cytometry was used to detect the presence of anti-AdAb (IgM and IgG) in sera from patients with biopsy-proven NAFLD (n=98) and in controls (n=49) without liver disease. Uni- and multivariate analysis was performed to draw associations between anti-AdAb IgM and IgG levels see more and

the different clinical variables. Patients with NAFLD had significantly higher levels of anti-AdAb IgM and significantly lower levels of AdAb IgG when compared to controls (p=0.002 and p<0.001, respectively). Patients with NASH had significantly higher levels of anti-AdAb IgM when compared to Non NASH NAFLD patients, p=0.04. In multivariate analysis, anti-AdAb IgM was independently associated with a higher risk for NASH [OR: 2.90(CI 1.18-7.16), p=0.02)]. Anti-AdAb IgM was also found to be independently associated with portal inflammation in patients with NAFLD [OR: 3.01(CI 1.15-7.90 p=0.02)]. Anti-AdAb IgM was independently associated with NAFLD and NASH while Anti-AdAb IgG was found to be protective against NAFLD. Anti-AdAb IgM was found specifically to be associated with the inflammatory processes in NAFLD. These findings indicate that the Anti-AdAb IgM and IgG may play an immunomodulatory role in the pathogenesis of NAFLD and NASH. "
“Stem cells have potential for therapy of liver diseases, but may also be involved in the formation of liver cancer.